Inhibikase Therapeutics (IKT)
Market Price (2/25/2026): $2.03 | Market Cap: $182.8 MilSector: Health Care | Industry: Biotechnology
Inhibikase Therapeutics (IKT)
Market Price (2/25/2026): $2.03Market Cap: $182.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -42% | Weak multi-year price returns2Y Excs Rtn is -49%, 3Y Excs Rtn is -122% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Neurodegenerative Disease Therapeutics. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -53 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -30% | ||
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 17.85 | ||
| Key risksIKT key risks include [1] the potential clinical failure of its lead drug candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -42% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Neurodegenerative Disease Therapeutics. |
| Weak multi-year price returns2Y Excs Rtn is -49%, 3Y Excs Rtn is -122% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -53 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -30% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 17.85 |
| Key risksIKT key risks include [1] the potential clinical failure of its lead drug candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Inhibikase Therapeutics (IKT) stock has gained about 40% since 10/31/2025 because of the following key factors:
1. Advancement of IKT-001 to a Global Pivotal Phase 3 Clinical Study in Pulmonary Arterial Hypertension (PAH). Inhibikase Therapeutics announced on November 20, 2025, its intention to advance IKT-001, a novel prodrug of imatinib mesylate, into a global pivotal Phase 3 clinical study for PAH, named IMPROVE-PAH, which is expected to commence in the first quarter of 2026. This significant progression in its lead investigational therapy followed positive feedback from the U.S. Food & Drug Administration (FDA) allowing for an immediate transition to a pivotal Phase 3 design from a previously planned Phase 2b study.
2. Accelerated Timeline for Potential FDA Approval. The revised study plan for IKT-001 in PAH, moving directly to a single pivotal Phase 3 study format, has the potential to accelerate the timeline to Phase 3 topline data readout and a possible New Drug Application (NDA) filing by approximately three years. This accelerated pathway to market for a critical therapy in a life-threatening condition significantly de-risks the development program and enhances the company's long-term value proposition.
Show more
1. Advancement of IKT-001 to a Global Pivotal Phase 3 Clinical Study in Pulmonary Arterial Hypertension (PAH). Inhibikase Therapeutics announced on November 20, 2025, its intention to advance IKT-001, a novel prodrug of imatinib mesylate, into a global pivotal Phase 3 clinical study for PAH, named IMPROVE-PAH, which is expected to commence in the first quarter of 2026. This significant progression in its lead investigational therapy followed positive feedback from the U.S. Food & Drug Administration (FDA) allowing for an immediate transition to a pivotal Phase 3 design from a previously planned Phase 2b study.
2. Accelerated Timeline for Potential FDA Approval. The revised study plan for IKT-001 in PAH, moving directly to a single pivotal Phase 3 study format, has the potential to accelerate the timeline to Phase 3 topline data readout and a possible New Drug Application (NDA) filing by approximately three years. This accelerated pathway to market for a critical therapy in a life-threatening condition significantly de-risks the development program and enhances the company's long-term value proposition.
Show more
Stock Movement Drivers
Fundamental Drivers
The 39.5% change in IKT stock from 10/31/2025 to 2/24/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 2242026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.47 | 2.05 | 39.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 90 | 90 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 2/24/2026| Return | Correlation | |
|---|---|---|
| IKT | 39.5% | |
| Market (SPY) | 0.8% | 29.0% |
| Sector (XLV) | 9.4% | 22.6% |
Fundamental Drivers
The 29.7% change in IKT stock from 7/31/2025 to 2/24/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 2242026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.58 | 2.05 | 29.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 90 | 90 | -0.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/24/2026| Return | Correlation | |
|---|---|---|
| IKT | 29.7% | |
| Market (SPY) | 9.0% | 31.1% |
| Sector (XLV) | 21.6% | 30.9% |
Fundamental Drivers
The -9.7% change in IKT stock from 1/31/2025 to 2/24/2026 was primarily driven by a -90.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2242026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.27 | 2.05 | -9.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 9 | 90 | -90.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2025 to 2/24/2026| Return | Correlation | |
|---|---|---|
| IKT | -9.7% | |
| Market (SPY) | 15.2% | 34.6% |
| Sector (XLV) | 8.9% | 30.2% |
Fundamental Drivers
The -51.6% change in IKT stock from 1/31/2023 to 2/24/2026 was primarily driven by a -95.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2242026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.24 | 2.05 | -51.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 4 | 90 | -95.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2023 to 2/24/2026| Return | Correlation | |
|---|---|---|
| IKT | -51.6% | |
| Market (SPY) | 75.4% | 16.3% |
| Sector (XLV) | 23.9% | 14.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IKT Return | -79% | -66% | -58% | 156% | -37% | -12% | -96% |
| Peers Return | -26% | -13% | -15% | -50% | -32% | 2% | -81% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| IKT Win Rate | 42% | 25% | 42% | 50% | 42% | 50% | |
| Peers Win Rate | 33% | 58% | 54% | 38% | 56% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| IKT Max Drawdown | -80% | -69% | -73% | -11% | -57% | -27% | |
| Peers Max Drawdown | -37% | -32% | -42% | -51% | -49% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, AKTS, ALPS, DCOY, DFTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/24/2026 (YTD)
How Low Can It Go
| Event | IKT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.3% | -25.4% |
| % Gain to Breakeven | 5788.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -30.3% | -33.9% |
| % Gain to Breakeven | 43.5% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
Compare to VRTX, AKTS, ALPS, DCOY, DFTX
In The Past
Inhibikase Therapeutics's stock fell -98.3% during the 2022 Inflation Shock from a high on 2/2/2021. A -98.3% loss requires a 5788.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
AI Analysis | Feedback
- A biotech company aiming to be the Vertex Pharmaceuticals for Parkinson's disease.
- A smaller, clinical-stage Biogen, but exclusively focused on developing a disease-modifying treatment for Parkinson's.
AI Analysis | Feedback
- IkT-148009: A lead drug candidate primarily developed to treat and potentially halt the progression of Parkinson's disease by inhibiting the c-Abl kinase.
- IkT-007N1: A drug candidate designed to treat certain cancers, such as Philadelphia chromosome-positive leukemias and gastrointestinal stromal tumors, by inhibiting the c-Abl kinase.
AI Analysis | Feedback
Inhibikase Therapeutics (symbol: IKT) is a clinical-stage biopharmaceutical company focused on the development of treatments for neurodegenerative diseases, particularly Parkinson's disease.
As a clinical-stage company, Inhibikase Therapeutics does not currently have any commercial products approved for sale. Therefore, the company does not have "major customers" in the traditional sense that purchase its products, whether they be other companies or individual consumers.
The company is primarily engaged in research and development, conducting clinical trials for its lead product candidates. If and when its drug candidates receive regulatory approval, Inhibikase Therapeutics would typically sell its products through pharmaceutical distributors to healthcare providers, pharmacies, and hospitals, who would then dispense them to patients. At that future stage, its "customers" would be these larger distribution and healthcare entities, rather than individuals directly.
AI Analysis | Feedback
nullAI Analysis | Feedback
Mark Iwicki, Chief Executive Officer
Mr. Iwicki has more than 30 years of experience in the biopharmaceutical industry. He previously served as Chief Executive Officer of KALA BIO, Civitas Therapeutics, and Sunovion Pharmaceuticals Inc. Additionally, he was President and Chief Executive Officer of Blend Therapeutics and President and Chief Operating Officer at Sepracor. Mr. Iwicki also held management positions at Novartis Pharmaceuticals Corporation, Astra Merck Inc., and Merck & Co.
David McIntyre, Chief Financial Officer
Mr. McIntyre has over two decades of executive experience in the life sciences sector, holding various C-suite roles at both public and private biotech and medical device entities, including Anthos Therapeutics, Inc., Tessa Therapeutics, Inc., and HeartWare International, Inc. He spent nearly ten years as a Partner at Apple Tree Partners, a multi-billion-dollar life sciences venture capital and growth equity fund, indicating a pattern of involvement with private equity-backed companies. Before entering the life sciences industry, he practiced as a senior attorney specializing in mergers and acquisitions, initial public offerings, and corporate law at Baker McKenzie and KPMG.
Chris Cabell, MD MHS FACC, President, Head of Research and Development, and Chief Medical Officer
Dr. Cabell previously served as Chief Executive Officer of CorHepta Pharmaceuticals, which was acquired by Inhibikase. He also held positions as Head of Clinical Development and Chief Medical Officer at Zura Bio and Emergent BioSolutions.
John Adams, PhD, Chief Scientific Officer
Dr. Adams was a co-founder and Chief Scientific Officer at CorHepta, joining Inhibikase from there. His prior roles include Senior Vice President of Discovery Biology at Iambic Therapeutics, Senior Vice President of Translational Science at Reneo Pharmaceuticals, and Head of Research at Arena Pharmaceuticals.
Timothy Pigot, Chief Commercial and Strategy Officer
Mr. Pigot has over three decades of experience in the pharmaceutical industry, encompassing both large pharma and startup organizations. Most recently, he served as Chief Commercial Officer of Aerovate Therapeutics. Previously, Mr. Pigot was Vice President of Marketing for MyoKardia, where he led the commercial launch strategy for mavacamten, a cardiac myosin inhibitor. He also held leadership positions in sales, marketing, and operations at Gilead Sciences and Pfizer.
AI Analysis | Feedback
The key risks to Inhibikase Therapeutics (IKT) are primarily associated with the inherent uncertainties of clinical drug development, ongoing legal scrutiny, and intense market competition.
- Clinical Development Risk: The most significant risk for Inhibikase Therapeutics is the potential failure of its lead drug candidate, IkT-001Pro, to demonstrate sufficient efficacy or an acceptable safety profile in ongoing and future clinical trials for Pulmonary Arterial Hypertension (PAH). The company has previously experienced a clinical failure with another candidate, risvodetinib, in Parkinson's disease, highlighting the inherent challenges in drug development. While IkT-001Pro aims to improve upon the safety and tolerability issues that hindered the approval of its active ingredient, imatinib, in PAH, its efficacy and safety in humans remain unproven. Clinical trials are inherently uncertain, with participants facing potential side effects ranging from mild to severe, and earlier phases carry higher levels of uncertainty regarding treatment effects. For example, a prior clinical hold was placed on IKT-148009 (risvodetinib) by the FDA due to safety concerns and the need for more comprehensive monitoring of potential vision-related adverse events.
- Shareholder Investigation and Corporate Governance Risk: Inhibikase Therapeutics is currently the subject of a shareholder investigation by Purcell & Lefkowitz LLP, which is examining potential breaches of fiduciary duty by the company's directors. This legal scrutiny introduces material risks, including the possibility of legal penalties, shareholder lawsuits, and reputational damage, all of which could significantly impede the company's clinical progress and financial stability. Issues such as allegations of overpriced executive compensation or a lack of transparency in decision-making could also deter potential investors.
- Competition: The competitive landscape within the Pulmonary Arterial Hypertension (PAH) market is intensifying. Notable competitors, such as Merck with its drug sotatercept, have demonstrated significant efficacy in PAH, setting a high bar for new treatments. This increasing competition poses a substantial external risk to the market potential and commercial success of IkT-001Pro, even if it proves to be clinically effective.
AI Analysis | Feedback
The advancement of LRRK2 inhibitors, specifically Denali Therapeutics' DNL151 (in collaboration with Biogen), represents a clear emerging threat. Denali announced positive interim analysis from their Phase 2b LUMA study of DNL151 in Parkinson's Disease in September 2023, leading to its progression into Phase 3 clinical trials. DNL151 is designed as a disease-modifying therapy for Parkinson's Disease, directly competing with Inhibikase Therapeutics' lead candidate, IkT-148009, which is also a disease-modifying therapy for Parkinson's Disease and is currently in Phase 2 trials. The progression of a competitor's drug to a later clinical stage with positive data in the same indication and with a similar therapeutic goal constitutes a significant emerging competitive threat.
AI Analysis | Feedback
Inhibikase Therapeutics (IKT) is developing product candidates for Parkinson's disease and Pulmonary Arterial Hypertension (PAH).
- Parkinson's Disease (for product candidate IkT-148009/Risvodetinib): The global Parkinson's disease drugs market was valued at approximately USD 7.17 billion in 2024 and is projected to grow to about USD 13.46 billion by the end of 2032. North America held the largest share of this market, with approximately 34.86% in 2024, accounting for USD 2.50 billion.
- Pulmonary Arterial Hypertension (PAH) (for product candidate IkT-001Pro): The global market for Pulmonary Arterial Hypertension is valued at approximately USD 7.7 billion annually.
AI Analysis | Feedback
Inhibikase Therapeutics (IKT), a clinical-stage biotechnology company, anticipates future revenue growth over the next 2-3 years to be primarily driven by the advancement and potential commercialization of its key drug candidates. As of current forecasts, the company is not expected to generate revenue from product sales in the immediate future, but significant milestones in its pipeline are critical precursors to future revenue streams. The expected drivers of future revenue growth for Inhibikase Therapeutics are: * Advancement and Positive Clinical Trial Outcomes for Risvodetinib (Risvo) in Parkinson's Disease (PD): Inhibikase's lead program, risvodetinib for Parkinson's disease, completed enrollment for its Phase 2 201 trial. Top-line data from this trial are expected in November 2024, with discussions with the FDA regarding Phase 3 plans anticipated by the end of 2024, and potential initiation of Phase 3 trials in Q1/Q2 2025. Successful progression through these stages is crucial for eventual market approval and revenue generation. * Advancement and Positive Clinical Trial Outcomes for IkT-001Pro in Pulmonary Arterial Hypertension (PAH): The company has received Investigational New Drug (IND) clearance from the FDA to proceed with a Phase 2b trial for IkT-001Pro in pulmonary arterial hypertension. Clinical development for this indication is projected to commence in late 2024 or early 2025, pending IND clearance. The global PAH market, valued at approximately $7.66 billion, represents a substantial commercial opportunity for IkT-001Pro, which is believed to offer an improved safety and tolerability profile compared to existing treatments. * Advancement and Potential Market Penetration of IkT-001Pro for Chronic Myeloid Leukemia (CML) with an Improved Safety Profile: Inhibikase Therapeutics has completed the pivotal phase of its 501 trial, evaluating the bioequivalence of IkT-001Pro with 400-milligram imatinib mesylate for CML. The company is considering further evaluation of bioequivalent doses with high-dose 600-milligram imatinib mesylate, aiming to demonstrate a potential safety benefit. High-dose imatinib mesylate is commonly used for CML but often poorly tolerated, a shortcoming that IkT-001Pro may overcome, potentially allowing it to capture market share. * Strategic Partnerships and Licensing Agreements: As a clinical-stage company, Inhibikase Therapeutics relies on significant investment for research and development. Securing strategic partnerships or licensing agreements for its pipeline assets could provide crucial non-dilutive funding, leverage the commercialization expertise and resources of larger pharmaceutical companies, and accelerate market access. Such agreements could generate revenue through upfront payments, milestone achievements, and future royalties, thereby fueling continued development and growth. The company also states that its multi-therapeutic pipeline for neurodegenerative diseases and its RAMPâ„¢ medicinal chemistry program for follow-on compounds could lead to additional development opportunities.AI Analysis | Feedback
Share Issuance
- Inhibikase Therapeutics completed its Initial Public Offering (IPO) on December 23, 2020, issuing 1,800,000 shares of common stock at $10.00 per share, resulting in gross proceeds of $18 million.
- On May 20, 2024, the company announced the pricing of a registered direct offering and warrant inducement, generating aggregate gross proceeds of $4.0 million.
- In October 2024, Inhibikase Therapeutics announced a private offering of approximately $110 million, which included the sale of 58.31 million shares of common stock and pre-funded warrants for 21.985 million shares.
Inbound Investments
- In October 2024, Inhibikase Therapeutics secured an aggregate investment of up to approximately $275 million from healthcare-focused investment funds, led by Soleus Capital.
Outbound Investments
- On February 21, 2025, Inhibikase Therapeutics acquired CorHepta Pharmaceuticals for $15 million, which was paid through the issuance of 4,979,101 shares of Inhibikase Therapeutics common stock.
Capital Expenditures
- In the last 12 months, capital expenditures for Inhibikase Therapeutics were approximately $4 million.
- For the quarter ended June 30, 2025, purchases of equipment and improvements amounted to $13,399.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Inhibikase Therapeutics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to IKT.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.5% | 5.5% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -15.6% | -15.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.4% | 19.4% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 15.3% | 15.3% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -42.4% | -42.4% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.75 |
| Mkt Cap | 61.9 |
| Rev LTM | 0 |
| Op Inc LTM | -29 |
| FCF LTM | -15 |
| FCF 3Y Avg | -16 |
| CFO LTM | -15 |
| CFO 3Y Avg | -16 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.9% |
| Rev Chg 3Y Avg | 10.4% |
| Rev Chg Q | 9.5% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Mgn LTM | 37.9% |
| Op Mgn 3Y Avg | 24.7% |
| QoQ Delta Op Mgn LTM | 38.7% |
| CFO/Rev LTM | 30.3% |
| CFO/Rev 3Y Avg | 20.5% |
| FCF/Rev LTM | 26.6% |
| FCF/Rev 3Y Avg | 17.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 61.9 |
| P/S | 10.3 |
| P/EBIT | 11.5 |
| P/E | 13.7 |
| P/CFO | 13.4 |
| Total Yield | -11.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -50.2% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.9% |
| 3M Rtn | 13.4% |
| 6M Rtn | 11.4% |
| 12M Rtn | -0.4% |
| 3Y Rtn | 7.0% |
| 1M Excs Rtn | -1.5% |
| 3M Excs Rtn | 10.0% |
| 6M Excs Rtn | 1.9% |
| 12M Excs Rtn | -15.2% |
| 3Y Excs Rtn | -61.4% |
Price Behavior
Price Behavior
| Market Price | $2.05 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 12/23/2020 | |
| Distance from 52W High | -17.3% | |
| 50 Days | 200 Days | |
| DMA Price | $1.72 | $1.72 |
| DMA Trend | down | up |
| Distance from DMA | 19.4% | 19.4% |
| 3M | 1YR | |
| Volatility | 78.7% | 81.1% |
| Downside Capture | 69.66 | 207.63 |
| Upside Capture | 230.20 | 157.79 |
| Correlation (SPY) | 21.4% | 34.6% |
IKT Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.06 | 1.17 | 1.55 | 1.97 | 1.47 | 1.05 |
| Up Beta | 8.72 | 5.90 | 2.82 | 4.35 | 1.67 | 1.27 |
| Down Beta | -1.97 | 0.37 | 0.84 | 0.46 | 0.69 | 0.84 |
| Up Capture | -13% | 76% | 171% | 188% | 225% | 35% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 7 | 20 | 28 | 53 | 103 | 331 |
| Down Capture | 730% | 93% | 156% | 198% | 147% | 106% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 21 | 33 | 66 | 133 | 387 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IKT | |
|---|---|---|---|---|
| IKT | -33.9% | 82.7% | -0.15 | - |
| Sector ETF (XLV) | 9.3% | 17.3% | 0.35 | 31.0% |
| Equity (SPY) | 15.6% | 19.3% | 0.63 | 35.0% |
| Gold (GLD) | 76.8% | 25.7% | 2.19 | 8.8% |
| Commodities (DBC) | 9.1% | 16.9% | 0.35 | 12.0% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.29 | 25.2% |
| Bitcoin (BTCUSD) | -33.3% | 45.1% | -0.76 | 22.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IKT | |
|---|---|---|---|---|
| IKT | -47.0% | 96.4% | -0.20 | - |
| Sector ETF (XLV) | 7.9% | 14.5% | 0.36 | 12.6% |
| Equity (SPY) | 13.4% | 17.0% | 0.62 | 16.3% |
| Gold (GLD) | 23.5% | 17.1% | 1.12 | 7.3% |
| Commodities (DBC) | 10.6% | 19.0% | 0.45 | 2.8% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 12.9% |
| Bitcoin (BTCUSD) | 4.3% | 57.1% | 0.30 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IKT | |
|---|---|---|---|---|
| IKT | -28.9% | 96.4% | -0.23 | - |
| Sector ETF (XLV) | 11.0% | 16.5% | 0.55 | 12.8% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 16.8% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 6.8% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 3.2% |
| Real Estate (VNQ) | 6.8% | 20.7% | 0.29 | 13.1% |
| Bitcoin (BTCUSD) | 65.9% | 66.7% | 1.05 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/14/2025 | -0.7% | -2.6% | 3.9% |
| 8/14/2025 | 2.3% | -1.8% | -6.4% |
| 3/27/2025 | -3.4% | -16.7% | -7.2% |
| 11/17/2022 | 3.6% | -3.6% | -25.9% |
| 4/1/2021 | -4.8% | -9.8% | -17.0% |
| SUMMARY STATS | |||
| # Positive | 2 | 0 | 1 |
| # Negative | 3 | 5 | 4 |
| Median Positive | 3.0% | 3.9% | |
| Median Negative | -3.4% | -3.6% | -12.1% |
| Max Positive | 3.6% | 3.9% | |
| Max Negative | -4.8% | -16.7% | -25.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/27/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sands, Capital Life Sciences Pulse Fund Ii, Lp | Direct | Buy | 11242025 | 1.45 | 2,068,965 | 2,999,999 | 18,877,499 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.